KR20020008489A - Diarrhea treatment agent for livestock and preparation method thereof - Google Patents

Diarrhea treatment agent for livestock and preparation method thereof Download PDF

Info

Publication number
KR20020008489A
KR20020008489A KR1020000041697A KR20000041697A KR20020008489A KR 20020008489 A KR20020008489 A KR 20020008489A KR 1020000041697 A KR1020000041697 A KR 1020000041697A KR 20000041697 A KR20000041697 A KR 20000041697A KR 20020008489 A KR20020008489 A KR 20020008489A
Authority
KR
South Korea
Prior art keywords
weight
livestock
therapeutic agent
soybean
diarrhea
Prior art date
Application number
KR1020000041697A
Other languages
Korean (ko)
Inventor
강준구
Original Assignee
강준구
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 강준구 filed Critical 강준구
Priority to KR1020000041697A priority Critical patent/KR20020008489A/en
Publication of KR20020008489A publication Critical patent/KR20020008489A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

PURPOSE: A therapeutic agent in diarrhea of domestic animal and its producing method are provided, which agent has an improved germicidal activity with using a small amount of antibiotics and can increase the weight of domestic animals. CONSTITUTION: The therapeutic agent contains 75 to 85 wt.% of corn powder, 5 to 15 wt.% of soybean extract, 3 to 6 wt.% of dried wormwood, 3 to 6 wt.% of soybean starch and microorganism, wherein the microorganism is Bacillus subtilis which is nonpathogenic and secrets a large amount of secretion protein, Bacitracin. Its production method comprises the steps of: mixing 75 to 85 wt.% of corn powder and 5 to 15 wt.% of soybean extract; drying and sterilizing the mixture at 130 deg.C; and adding 3 to 6 wt.% of dried wormwood, 3 to 6 wt.% of soybean starch and microorganism.

Description

가축 설사 치료제 및 그의 제조 방법{DIARRHEA TREATMENT AGENT FOR LIVESTOCK AND PREPARATION METHOD THEREOF}Livestock diarrhea therapeutic agent and its manufacturing method {DIARRHEA TREATMENT AGENT FOR LIVESTOCK AND PREPARATION METHOD THEREOF}

본 발명은 항생제를 소량 사용하더라도 그 자체로서 살균력이 강한 가축 설사 치료제 및 그의 제조 방법에 관한 것으로, 더욱 상세하게 옥수수 전분, 메주콩 엑기스, 대두 전분, 쑥 및 미생물 종균을 혼합하여 제조된 것을 특징으로 하는 가축 설사 치료제 및 그의 제조 방법에 관한 것이다.The present invention relates to a livestock diarrhea therapeutic agent and a method for producing livestock diarrhea, which is strong in itself, even if a small amount of antibiotic, more specifically, characterized in that the corn starch, soybean extract, soybean starch, mugwort and microbial spawn mixed The present invention relates to a livestock diarrhea therapeutic agent and a method for producing the same.

가축의 설사는 장내 자극성 물질 및 독성 물질을 제거하기 위한 소화관의 생리적 방어 기전으로서 대부분 포도상 구균의 독소에 의한 식중독, 콜레라, 대장균의 장 독소 즉, 엔테로톡신(enterotoxin;균체외 독소)에 의하여 유발된다. 상기 설사가 지속될 경우에는 병원균등 설사의 원인을 규명하여 치료해야 한다. 치료 방법중 가장 일반적인 방법은 항균제의 투여이다.Livestock diarrhea is a physiological defense mechanism of the digestive tract to remove intestinal irritants and toxic substances, mostly caused by food poisoning caused by staphylococcus toxin, enterotoxin of cholera and E. coli, or enterototoxin (extracellular toxin). . If the diarrhea persists, the cause of diarrhea, such as pathogens, should be identified and treated. The most common method of treatment is the administration of an antimicrobial agent.

항균제, 즉 항생 물질이란 과거에는 여러 종의 미생물(세균, 곰팡이, 방사선균)에 의해서 생산되는 물질로 다른 미생물의 생장을 억제하거나 또는 죽이는 물질로 정의되었다. 그러나 현재는 합성 화학의 발전으로 많은 항균 능력을 갖는 물질이 합성에 의해 개발되고 이러한 합성 항균제도 항균제에 포함된다. 항균제들은 물리적, 화학적 및 약리학적 성상이 다르며 항균 범위, 작용 기전등이 다르다. 기존의 항균제를 그 작용 기전에 따라 분류하면 다음과 같다. 즉,Antimicrobials, or antibiotics, were previously produced by a variety of microorganisms (bacteria, fungi, radiation bacteria) and were defined as substances that inhibit or kill the growth of other microorganisms. However, at present, with the development of synthetic chemistry, substances having a lot of antibacterial ability are developed by synthesis, and such synthetic antimicrobial agents are included in antimicrobial agents. Antimicrobials differ in physical, chemical and pharmacological properties, and differ in their antimicrobial range and mechanism of action. Existing antimicrobial agents are classified according to their mechanism of action as follows. In other words,

(1) 세균 세포벽 합성을 억제하거나 또는 세포벽 분해 효소의 활성화로 항균 작용을 나타내는 제제 : 페니실린, 세팔로스포린 등(1) Agents that inhibit bacterial cell wall synthesis or exhibit antimicrobial activity by activation of cell wall degrading enzymes: penicillin, cephalosporin, etc.

(2) 세균 세포막에 직접 작용하여 세포막 투과성을 변화시키는 제제 : 폴리믹신, 콜리스티메테이트 등(2) Agents that directly affect bacterial cell membranes to change cell membrane permeability: polymyxin, colistimate, etc.

(3) 세균 리보좀의 기능에 영향을 주어 단백질 활성을 가역적으로 억제하는 약물 : 클로람페니콜, 테트라싸이클린, 에리트로마이신 등(3) Drugs that affect the function of bacterial ribosomes and reversibly inhibit protein activity: chloramphenicol, tetracycline, erythromycin, etc.

(4) 핵산 대사에 영향을 주는 화합물 : 리파마이신, 퀴놀론, 메트로니다졸 등(4) Compounds affecting nucleic acid metabolism: rifamycin, quinolone, metronidazole, etc.

(5) 대사 길항 항균제 : 설폰아미드 등(5) metabolic antagonists: sulfonamides, etc.

(6) 핵산 유사 화합물 : 비드아라빈 등(6) nucleic acid-like compounds: bead arabine and the like

그러나 이들 항생 물질들을 생물체에 계속적으로 투여할 경우 약품에 대한 내성(tolerance)이 생기게 되므로 바람직하지 못하다. 예를 들어, 동물의 체내에서 항생제에 대한 내성이 생기게 되면, 세포가 유전학적으로 변성되어 세포벽으로부터 세포내로 유입된 약제들을 외부로 배출시키는 효소(예를 들어, p-당단백질)유전자의 발현에 돌연 변이가 발생하여 유전적 이상을 초래하게 되는등의 문제점이 있다.However, continuous administration of these antibiotics to living organisms is undesirable because it results in drug tolerance. For example, when an animal's body develops resistance to antibiotics, the cells are genetically denatured to express the enzymes (eg, p-glycoprotein) genes that excrete drugs introduced into the cells from the cell wall to the outside. There is a problem that a mutation occurs to cause a genetic abnormality.

따라서 항균제 사용량을 최소한으로 줄이더라도 그 자체로서 강한 살균력을갖는 가축 설사 치료제의 개발이 절실히 요구되고 있다.Therefore, even if the use of antimicrobial agents is minimized, the development of a livestock diarrhea therapeutic agent having strong sterilization power is in urgent need.

상기와 같은 문제점을 해결하기 위하여 본 발명의 목적은 항생제를 소량 사용하더라도 그 자체로서 강한 살균력을 나타내는 가축 설사 치료제 및 그의 제조 방법을 제공하는 것이다.In order to solve the above problems, it is an object of the present invention to provide a livestock diarrhea therapeutic agent and a method for producing the same, which exhibits strong sterilization power even when a small amount of antibiotic is used.

즉 본 발명의 목적은 옥수수 전분 75-85중량% 및 메주콩 엑기스 5-15중량%를 배합하여 130℃에서 건조 및 살균시키고 여기에 건조된 쑥 3-6중량% 및 대두 전분 3-6중량%를 가한후 미생물을 첨가시켜 제조된 것을 특징으로 하는 가축 설사 치료제 및 그의 제조 방법을 제공하는 것이다.That is, an object of the present invention is to combine 75-85% by weight of corn starch and 5-15% by weight of soybean extract, dried and sterilized at 130 ℃ and 3-6% by weight of dried mugwort and 3-6% by weight of soybean starch. The present invention provides a livestock diarrhea therapeutic agent and a method for producing the same, which are prepared by adding microorganisms after the addition.

이하 본 발명을 더욱 상세히 설명한다.Hereinafter, the present invention will be described in more detail.

본 발명의 가축 설사 치료제의 성분들은 옥수수 전분, 메주콩 엑기스, 쑥, 밀 및 대두 전분으로 구성되는데, 이하 상기 성분들에 대해서 설명하고자 한다.The components of the treatment of livestock diarrhea of the present invention are composed of corn starch, soybean extract, mugwort, wheat and soybean starch, which will be described below.

본 발명에서 옥수수 전분 및 대두 전분은 탄수화물로서, 본 발명의 미생물을 이용한 가축 설사 치료제에 사용되는 미생물의 탄소 공급원의 역할을 한다. 탄소 공급원(Carbon source)이란, 미생물 균체내에 흡수되어 에너지 또는 생산물로 변환되는 탄소화합물을 말한다. 이들은 상기 탄소 공급원을 섭취하여 해당 작용(glycolysis) 및 TCA 회로를 거쳐 전자 전달계를 통하여 에너지를 얻는다. 상기 탄소 공급원은 당질계 원료와 전분계 원소로 대별할 수 있는데, 이것들 중 상기 옥수수 전분 및 대두 전분은 전분계 원소로서 주로 방사선균, 곰팡이, 부탄올균등의 일부 세균에 의해 이용된다. 뿐만 아니라 가축의 물질 대사에도 이용되어 가축의 체중을 증가시켜 주는 역할을 한다. 상기 옥수수 전분의 함량은 전체 설사 치료제에 대해서 75-85중량%이며, 상기 대두 전분의 함량은 3-6중량%이다. 만일 상기 함량 범위를 벗어나는 경우에는 비용면에 있어서 합리적이지 못하므로 바람직하지 않다.Corn starch and soybean starch in the present invention is a carbohydrate, and serves as a carbon source of microorganisms used in the treatment of livestock diarrhea using the microorganism of the present invention. Carbon source refers to a carbon compound that is absorbed into microbial cells and converted into energy or products. They ingest the carbon source and obtain energy through an electron transfer system via glycolysis and the TCA circuit. The carbon source can be roughly classified into a saccharide-based raw material and a starch-based element, of which corn starch and soybean starch are mainly used by some bacteria such as radiation bacteria, molds, butanol bacteria, etc. as starch-based elements. In addition, it is used to metabolize livestock, which increases the weight of livestock. The corn starch content is 75-85% by weight relative to the total diarrhea therapeutic agent, the soybean starch content is 3-6% by weight. If it is out of the content range, it is not preferable because it is not reasonable in terms of cost.

본 발명에서 메주콩 엑기스는 본 발명에 의한 가축 설사 치료제에 포함된 미생물의 주요 질소 공급원으로서, 균체의 단백질 및 핵산등의 합성에 필요하다. 일반적으로 곰팡이는 공중 질소를 고정하지는 못한다. 예를 들어, 황산암모늄, 인산암모늄과 같은 암모늄, 질산염, 아질산염류등의 무기질 질소 화합물과 예를 들어, 요소, 펩톤등과 같은 유기질 질소 화합물의 형태로 이용한다. 일반적인 미생물의 질소 화합물 동화 과정은 'NH4(NO3) ---> 아미노산 --->단백질'로 된다.The soybean extract in the present invention is a major nitrogen source of microorganisms included in the livestock diarrhea therapeutic agent according to the present invention, and is required for the synthesis of proteins and nucleic acids of cells. In general, mold does not fix air nitrogen. For example, it is used in the form of inorganic nitrogen compounds, such as ammonium sulfate, ammonium, such as ammonium sulfate and ammonium phosphate, nitrate, nitrite, and organic nitrogen compounds, such as urea and peptone. Normal microbial nitrogen compound assimilation process is 'NH 4 (NO 3 ) ---> amino acid --->protein'.

뿐만 아니라 상기 메주콩 엑기스에는 단백질, 인지질 이외에 체 구성에 필요한 당분, 조섬유, 칼슘, 비타민 B1, B2등이 함유되어 있어서 체내 영양을 골고루 충족시켜 준다. 상기 메주콩 엑기스의 함량은 5-15중량%인 것이 바람직하다. 만일 상기 함량이 5중량% 미만인 경우에는 본 발명의 효과를 충분히 나타낼 수 없게 되어 좋지 않고, 만일 상기 함량이 15중량%를 초과할 경우에는 비경제적이므로 좋지 않다.In addition, the soybean extract contains sugar, crude fiber, calcium, vitamin B1, B2, etc. necessary for the composition of the body in addition to protein and phospholipids to satisfy the nutrition of the body evenly. The content of the soybean extract is preferably 5-15% by weight. If the content is less than 5% by weight it may not be sufficient to exhibit the effects of the present invention, and if the content is more than 15% by weight is not economical because it is not good.

본 발명에서 쑥은 국화과에 속하는 다년생 식물이며 강알칼리성 식품으로서 산성 체질을 개선시키고 피를 맑게 해준다. 또한 상기 쑥은 각종 약품, 비료,농약, 병원균독등의 독소를 분해시켜 체외로 배출시키는 강력한 해독제이다. 쑥은 항암 작용을 하는 풍부한 엽록소와 식물성 섬유, 양질의 미네랄 그리고 다양하고 풍부한 비타민등을 함유하고 있다. 상기 쑥을 첨가함으로써 본 발명의 가축 설사치료제의 약효를 상승시킬 수 있으며, 따라서 가축에 투여되는 항생제의 양을 상대적으로 감소시킬 수 있다. 상기 쑥의 함량은 전체 설사 치료제에 대해서 3-6중량%인 것이 바람직하다. 만일 상기 함량이 3중량% 미만인 경우에는 본 발명의 설사 치료제의 효과를 얻을 수 없게 되어 좋지 않고, 만일 상기 함량이 6중량%를 초과하는 경우에는 비용면에서 경제적이지 못하게 되어 좋지 않다.In the present invention, wormwood is a perennial plant belonging to the Asteraceae, and it is a strong alkaline food that improves acidic constitution and clears blood. In addition, the mugwort is a powerful antidote for decomposing toxins such as various drugs, fertilizers, pesticides, pathogens and the like to be discharged to the body. Mugwort contains abundant anti-cancer chlorophyll, vegetable fiber, high quality minerals and various rich vitamins. The addition of the wormwood can increase the efficacy of the livestock diarrhea therapeutic agent of the present invention, and thus can relatively reduce the amount of antibiotic administered to the livestock. The content of the wormwood is preferably 3-6% by weight based on the total diarrhea treatment. If the content is less than 3% by weight it is not possible to obtain the effect of the diarrhea therapeutic agent of the present invention, and if the content is more than 6% by weight it is not economical in terms of cost.

본 발명에서 미생물은 비병원성이며 분비 단백질을 다량으로 배출시키는 바실러스 속(Bacillussp)의 바실러스 서브틸리스(Bacillus subtilis)를 사용하였다.In the present invention, the microorganisms are non-pathogenic and Bacillus subtilis of Bacillus sp, which releases a large amount of secreted proteins, was used.

상기 바실러스 서브틸리스의 대표적인 분비 단백질로서는 항생 물질인 바시트라신(Bacitracin)을 들 수 있는데, 상기 바시트라신은 펩티드성 항생제(peptide antibiotics)로서 병원성 세균의 세포벽 합성을 저해하거나 또는 C55-이소프레닐피로포스페이트(C55-isoprenylpyrophosphate)가 C55-이소프레닐포스페이트(C55-isoprenylphosphate)로 탈인산화(dephosphorylation)되는 것을 차단함으로써 항균 작용을 나타낸다. 뿐만 아니라 상기 바시트라신은 동물의 성장 촉진제로서의 역할도 갖는데, 즉 리그닌-바시트라신 복합체(lignin-bacitracin complex), 바시트라신 메틸렌 디스알리싸이클레이트(bacitracin methylen disalicyclate), 아연 또는 마그네슘염의 형태로 사용되어 가축의 성장율 및 증체율을 상승시킨다.Representative secretory proteins of the Bacillus subtilis include the antibiotic Bacitracin (Bacitracin), a peptide peptide antibiotics (peptide antibiotics) to inhibit the cell wall synthesis of pathogenic bacteria or C55-isoprenyl It exhibits antimicrobial activity by blocking dephosphorylation of pyrophosphate (C55-isoprenylpyrophosphate) with C55-isoprenylphosphate. In addition, the bacitracin has a role as an animal growth promoter, that is, in the form of lignin-bacitracin complex, bacitracin methylen disalicyclate, zinc or magnesium salts. It raises the growth rate and the increase rate of the livestock.

이상과 같이 본 발명에서 사용되는 미생물은 당업자가 용이하게 입수할 수있는 균주들이다.Microorganisms used in the present invention as described above are strains that can be easily obtained by those skilled in the art.

이상과 같은 재료들을 사용하여 본 발명의 항생제 대체 가축 설사 치료제가 제조된다. 즉, 본 발명의 항생제 대체 가축 설사 치료제는 옥수수 전분 75-85중량% 및 메주콩 엑기스 5-15중량%를 배합하여 130℃에서 건조 및 살균시키고 여기에 건조된 쑥 3-6중량%, 대두 전분 3-6중량% 및 상기 미생물 균주를 가하여 제조된다.The antibiotic replacement livestock diarrhea therapeutic agent of this invention is manufactured using the above materials. That is, the antibiotic replacement livestock diarrhea therapeutic agent of the present invention contains 75-85% by weight of corn starch and 5-15% by weight of soybean extract, dried and sterilized at 130 ° C, and dried mugwort 3-6% by weight, soybean starch 3 Prepared by adding -6% by weight and the microbial strain.

이하 실시예를 들어 본 발명을 구체화할 것이며 다음의 실시예는 어디까지나 본 발명을 예시하기 위한 목적으로 기재된 것이지 본 발명의 보호 범위를 제한하고자 하는 것은 아니다.The present invention will be described with reference to the following examples and the following examples are described for the purpose of illustrating the present invention only, and are not intended to limit the protection scope of the present invention.

실시예Example

옥수수 전분 80중량%, 메주콩 엑기스 10중량%를 배합하여 130℃에서 건조 및 살균시킨후 여기에 쑥 분말 5중량% 및 대두 전분 5중량% 및 바실러스 서브틸리스 종균을 2.7×108 CFU/㎖ 가하여 본 발명의 가축 설사 치료제를 제조하였다.80% by weight of corn starch and 10% by weight of soybean extract were mixed and dried and sterilized at 130 ° C. Then, 5% by weight of mugwort powder, 5% by weight of soybean starch and Bacillus subtilis spawn were added to 2.7 × 108 CFU / ml. A livestock diarrhea therapeutic agent of the invention was prepared.

이후 대표적인 설사 원인균인 에스케리챠 콜라이(Escherichia coli) 및 스타필로코커스 아우레우스(Staphylococcus aureus) 균주를 브레인 하트 인퓨전 배양액(Brain Heart Infusion Broth)을 사용하여 인큐베이터(덕우 과학)에서 진탕 배양시킨후 배양된 세균을 접종 균수 1-9×105CFU/ml로 희석시켰다. 그리고나서 멸균된 캡 튜브(cap tube)에 옥수수 전분 80중량%, 메주콩 엑기스 10중량% 및 건조쑥 5중량%, 대두 전분 5중량% 및 바실러스 서브틸리스 종균을 혼합하여 제조한 시료를 20ml 넣고 상기 희석시킨 세균 배양액을 0.2ml 접종시켜 5분, 10분이 경과한 후의 세균수를 콜로니 카운터(colony countor ; 덕우 과학)세균수 감소율을 각각 측정하였다.Then, Escherichia coli and Staphylococcus aureus strains, which are representative causes of diarrhea, were cultured by shaking culture in an incubator (Deokwoo Science) using Brain Heart Infusion Broth. Bacteria were diluted to 1-9 × 10 5 CFU / ml. Then, 20 ml of the sample prepared by mixing 80% by weight of corn starch, 10% by weight of soybean extract and 5% by weight of dried mugwort, 5% by weight of soybean starch and Bacillus subtilis spawn in a sterile cap tube. 0.2 ml of the diluted bacterial culture was inoculated, and the number of bacteria after 5 minutes and 10 minutes had elapsed was measured by the colony counter (Duckwoo Science).

이때 세균 감소율은 다음과 같이 계산할 수 있다.At this time, the bacterial reduction rate can be calculated as follows.

(상기 수학식중, A는 초기 세균수 ; B는 일정 시간 경과후의 세균수를 나타냄)(In the above formula, A is the initial number of bacteria; B represents the number of bacteria after a certain time elapses.)

균주명Strain name 경과 시간Elapsed time 생존 세균수Viable bacteria 세균 감소율Bacterial reduction rate 에스케리챠 콜라이Escherichia coli 00 7.5×105 7.5 × 10 5 55 2.0×105 2.0 × 10 5 73.373.3 1010 0.2×105 0.2 × 10 5 98.398.3 스타필로코커스 아우레우스Staphylococcus aureus 00 4.8×105 4.8 × 10 5 55 1.5×105 1.5 × 10 5 68.7568.75 1010 0.25×105 0.25 × 10 5 94.7994.79

[단 위][unit]

*경과 시간 : 분* Elapsed time: minutes

*생존 세균수 : CFU/ml* Number of living bacteria: CFU / ml

*세균 감소율 : %* Bacterial Reduction Rate:%

상기의 실시예의 결과를 통하여 확인되는 바와 같이, 본 발명의 가축 설사 치료제는 포유 동물의 장내 병원성 세균에 대한 살균력이 뛰어난 이점을 갖는다.As confirmed through the results of the above embodiment, the livestock diarrhea therapeutic agent of the present invention has an excellent sterilizing power against the enteric pathogenic bacteria of mammals.

Claims (3)

옥수수 전분 75-85중량% 및 메주콩 엑기스 5-15중량%를 배합하여 130℃에서 건조 및 살균시키고 여기에 건조된 쑥 3-6중량%, 대두 전분 3-6중량% 및 미생물을 가하여 제조하는 것을 특징으로 하는 가축 설사 치료제의 제조 방법.75-85% by weight of corn starch and 5-15% by weight of soybean extract, which are dried and sterilized at 130 ° C. and prepared by adding 3-6% by weight of dried mugwort, 3-6% by weight of soybean starch and microorganisms. A method for producing a livestock diarrhea therapeutic agent. 제 1항에 있어서, 상기 미생물로 바실러스 서브틸리스(Bacillus subtilis)를 사용하는 것을 특징으로 하는 가축 설사 치료제의 제조 방법.According to claim 1, Bacillus subtilis ( Bacillus subtilis ) is used as a method for producing livestock diarrhea therapeutics characterized in that the microorganism. 제 1항의 방법에 의하여 제조된 가축 설사 치료제.A livestock diarrhea therapeutic agent prepared by the method of claim 1.
KR1020000041697A 2000-07-20 2000-07-20 Diarrhea treatment agent for livestock and preparation method thereof KR20020008489A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020000041697A KR20020008489A (en) 2000-07-20 2000-07-20 Diarrhea treatment agent for livestock and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020000041697A KR20020008489A (en) 2000-07-20 2000-07-20 Diarrhea treatment agent for livestock and preparation method thereof

Publications (1)

Publication Number Publication Date
KR20020008489A true KR20020008489A (en) 2002-01-31

Family

ID=19679019

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020000041697A KR20020008489A (en) 2000-07-20 2000-07-20 Diarrhea treatment agent for livestock and preparation method thereof

Country Status (1)

Country Link
KR (1) KR20020008489A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960010012A (en) * 1994-09-17 1996-04-20 강성진 Immune Promoting and Hari Prevention Compositions in Animals and Preparations Containing the Same
US5540924A (en) * 1989-09-05 1996-07-30 Ajinomoto Company, Inc. Composition for the prevention and treatment of white diarrhea and diarrhea in livestock, etc.
WO1997033487A1 (en) * 1996-03-14 1997-09-18 Toyoaki Kubota Oral composition for animals
KR101177637B1 (en) * 2010-09-17 2012-08-27 주식회사 티엠에스 Apparatus of Membrane Welding Guide for LNG Carrier

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5540924A (en) * 1989-09-05 1996-07-30 Ajinomoto Company, Inc. Composition for the prevention and treatment of white diarrhea and diarrhea in livestock, etc.
KR960010012A (en) * 1994-09-17 1996-04-20 강성진 Immune Promoting and Hari Prevention Compositions in Animals and Preparations Containing the Same
WO1997033487A1 (en) * 1996-03-14 1997-09-18 Toyoaki Kubota Oral composition for animals
KR101177637B1 (en) * 2010-09-17 2012-08-27 주식회사 티엠에스 Apparatus of Membrane Welding Guide for LNG Carrier

Similar Documents

Publication Publication Date Title
KR101029346B1 (en) Combined microorganism fermented liquors having the effect of reducing odor gas and antibacterial effect, and methods of using the same
WO2019178309A1 (en) Probiotic composition and feed additive
CN108314722A (en) A kind of antibacterial peptide and its application
CN101199319A (en) Enzyme composite bactericide with broad-spectrum high-efficient bactericidal action and its preparation method
CN1927025A (en) Microecological feed addictive for accelerating fur-bearing animal growth
CN101986865A (en) Preparation of Bacillus licheniformis preparation for poultry
KR101818859B1 (en) Pseudomonas azotoformans strain KACC 92125P and composition for comprising the same
WO2005087241A1 (en) Infection-controlling agent for livestock, poultry or fish
CN102334610A (en) Antibiotic-free environment-friendly biological feed and production method thereof
CN105061564B (en) A kind of antibacterial peptide PD22
US5741494A (en) Immunopotentiative and infection-protective agent containing bacillus and egg white
WO2023050716A1 (en) Weissella confusa, culture method and use thereof
KR20020008489A (en) Diarrhea treatment agent for livestock and preparation method thereof
CN112515050B (en) Antibacterial animal growth promoter containing recombinant human lysozyme and application thereof
EP1894995B1 (en) Irilis biopreparation based on bacillus-strain bacteria, bacillus subtilis and bacillus licheniformis contained therein
CN101381757A (en) Solid fermentation preparation method of antibacterial peptide and application
Herich et al. The influence of short-term and continuous administration of Lactobacillus casei on basic haematological and immunological parameters in gnotobiotic piglets
CN105124163A (en) Peptide feed additive for improving intestinal environment and preparation method thereof
CN102000092A (en) New application of sulfadiazine sodium
KR101659062B1 (en) Pediococcus parvulus against pathogen of American Foulbrood microbial agent comprising the same and method for preventing pathogen using the same
CN111821322A (en) Poultry micro-ecological oral preparation capable of replacing antibiotics and application thereof
CN111109443A (en) Microecological preparation for livestock and poultry production and preparation method thereof
CN102462686A (en) Pharmaceutical composition used for preventing and treating colibacillosis in livestock and poultry
AU2021202114B2 (en) Probiotic compositions
CN108553635B (en) Pig-derived antibacterial peptide PMAP-36 sustained-release capsule

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
N231 Notification of change of applicant
E902 Notification of reason for refusal
E601 Decision to refuse application